Company profile for Mustang Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Mustang Bio, Inc. (“Mustang”), a Fortress Biotech Company, is a clinical‐stage biopharmaceutical company focused on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies in areas of unmet need. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund researc...
Mustang Bio, Inc. (“Mustang”), a Fortress Biotech Company, is a clinical‐stage biopharmaceutical company focused on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies in areas of unmet need. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
377 Plantation Street • Worcester, MA 01605
Telephone
Telephone
781-652-4500
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/07/07/3111023/0/en/Mustang-Bio-Granted-Orphan-Drug-Designation-by-U-S-FDA-for-MB-101-IL13Ra2-targeted-CAR-T-cells-to-Treat-Astrocytomas-and-Glioblastoma.html

GLOBENEWSWIRE
07 Jul 2025

https://www.globenewswire.com/news-release/2025/03/05/3037777/0/en/Mustang-Bio-Regains-Compliance-with-Nasdaq-Capital-Market-Requirement.html

GLOBENEWSWIRE
05 Mar 2025

https://www.globenewswire.com/news-release/2025/02/27/3034325/0/en/Mustang-Bio-Announces-Sale-of-Fixed-Assets-and-Exit-of-Facility.html

GLOBENEWSWIRE
27 Feb 2025

https://www.globenewswire.com/news-release/2025/02/11/3024607/0/en/Mustang-Bio-Regains-Compliance-with-Nasdaq-Minimum-Bid-Price-Requirement.html

GLOBENEWSWIRE
11 Feb 2025

https://www.globenewswire.com/news-release/2025/02/10/3023401/0/en/Mustang-Bio-Announces-Closing-of-8-Million-Public-Offering.html

GLOBENEWSWIRE
10 Feb 2025

https://www.globenewswire.com/news-release/2025/02/06/3021896/0/en/Mustang-Bio-Announces-Pricing-of-8-Million-Public-Offering.html

GLOBENEWSWIRE
06 Feb 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty